BioSig Announces Abstract Acceptance to Computing in Cardiology 2020
September 14 2020 - 3:00PM
- Novel algorithm can successfully reconstruct ECG lead
placements
- The method may improve the automated classification of
patient conditions and unlock new applications of clinical
value
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that the Company’s abstract
for ‘Computational Reconstruction of Electrocardiogram Lead
Placement’ was accepted for presentation at the 2020 Computing in
Cardiology Conference (CinC).
The abstract was co-authored by Dr. Alexander D. Wissner-Gross
of Reified LLC, Dr. Suraj Kapa of the Mayo Clinic, James Lee,
Natasha Drapeau, and Kenneth L. Londoner of BioSig Technologies,
Inc. The manuscript presents a method for computationally
reconstructing the spatial placement of electrocardiogram (ECG)
leads using only correlations between their recorded signals and
without requiring external calibration or other prior knowledge.
The work further examines the association of various cardiac
abnormalities with the reconstructed geometries and reviews
potential clinical applications of the method.
“We are encouraged by the early successes that Alex and his team
have demonstrated in developing machine learning solutions for PURE
EP(tm). From early disease detection to more accurate diagnosis to
improved decision making during treatment, the transformative
potential of artificial intelligence and machine learning in
healthcare is vast. We are excited to report on our progress during
the CinC 2020 and look forward to exploring further clinical
applications through novel AI-powered algorithms,” commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc.
“We found that electrophysiological waveforms could encode a
surprising amount of spatial information about the context in which
they were recorded and look forward to translating this and other
advanced biomedical signal analytics into clinical usage,” added
Dr. Wissner-Gross.
CinC 2020 takes place on September 13-16, 2020, in a hybrid of
live and online sessions, in Rimini, Italy. The Company’s abstract
will be presented virtually by Dr. Alexander D. Wissner-Gross, on
Tuesday, September 15, from 15:45-17:45 Central European Time
(09:45 – 11:45 Eastern Time).
Please view the CinC 2020 program using this link.
In December 2019, the Company announced that it partnered with
Cambridge, Massachusetts-based Reified LLC, a provider of advanced
artificial intelligence-focused technical advisory services to the
private sector. Initial machine learning and AI solutions developed
under the terms of this collaboration are focused on BioSig’s core
competencies in electrophysiology.
About Computing in CardiologyCinC provides a
forum for scientists and professionals from the fields of medicine,
physics, engineering, and computer science to discuss their current
research on topics about computing in cardiology and cardiovascular
physiology. About BioSig Technologies BioSig
Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed
to improve signal fidelity and uncover the full range of ECG
and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024